MSI-H
10 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations (NCT04969029) | Tianjin Medical University Cancer Institute and Hospital | 2021-06-01 |
| Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer (NCT04636008) | West China Hospital | 2020-08-14 |
| A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors (NCT03775850) | Evelo Biosciences, Inc. | 2018-12-19 |
| Study of the CD40 Agonistic Monoclonal Antibody APX005M (NCT02482168) | Apexigen America, Inc. | 2015-05-01 |
Track MSI-H automatically
Every clearance here is in the API, with alerts when new ones post.